A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
Alliance for Clinical Trials in Oncology
Dana-Farber Cancer Institute
Fudan University
City of Hope Medical Center
M.D. Anderson Cancer Center
Mayo Clinic
Fondazione Italiana Linfomi - ETS
Case Comprehensive Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
Northwestern University
Wake Forest University Health Sciences
Stanford University
University of Nebraska
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
University of Nebraska
Northwestern University
University of Nebraska
University of Nebraska
City of Hope Medical Center
Ruijin Hospital
The First Hospital of Jilin University
Massachusetts General Hospital
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Zhejiang University
Rutgers, The State University of New Jersey
Northwestern University
Northwestern University
Roswell Park Cancer Institute
Universität des Saarlandes
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Mayo Clinic
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
Mayo Clinic